Literature DB >> 18560954

[Follow up in head and neck cancer].

Csilla Neuchrist1, Michael Formanek.   

Abstract

Some principle questions rise in follow up of tumour patients: Is there a chance to detect tumour recurrence or a second primary early enough to give the patient reasonable options of cure or at least lead to a better survival? What means will be necessary to achieve this goal? Do the means justify the outcome? This paper determines and compares current regimens and strategies in the follow up of head and neck cancer patients. It stresses not only the questions stated above, but also stresses additional points of view in the follow up like speech and swallow rehabilitation, as well as social reintegration and psychological support of head and neck tumour patients. Standard follow up includes facilities for speech and swallow rehabilitation. Summarizing the literature follow up mainly is based on the clinical examination and the work up of the recent medical history. Since most relapses occur within the first two years, recommendation of visit-intervals is every two months, range should be risk-adapted. Up to now there is no evidence for better overall survival using sumptuous means like repeated panendoskopies, laboratory parameters, CT's, MRIs or PETs for detecting disease relapse in the asymptomatic patient. In high risk cancer patients the intervals will be shortened compared to the average schedule recommended. Additional tests will be initiated on demand only. Since clinical evaluation of symptoms in head and neck cancer patients is difficult to assess there is an increased responsibility with respect to the indication for extended diagnostic work up. Therefore this should be reserved for well equipped and highly trained ENT Oncologists.

Entities:  

Mesh:

Year:  2008        PMID: 18560954     DOI: 10.1007/s10354-008-0533-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  17 in total

1.  [Tumor after-care: goals, results and concepts].

Authors:  I Haas
Journal:  Laryngorhinootologie       Date:  2000-11       Impact factor: 1.057

Review 2.  Follow-up in patients treated for head and neck cancer: how frequent, how thorough and for how long?

Authors:  G B Snow
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

3.  Costs of posttreatment surveillance for patients with upper aerodigestive tract cancer.

Authors:  K S Virgo; R C Paniello; F E Johnson
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1998-05

4.  Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.

Authors:  C Kuropkat; B M Lippert; J A Werner
Journal:  Oncology       Date:  2002       Impact factor: 2.935

5.  Surgical decision making in upper aerodigestive tract cancer patient follow-up.

Authors:  Katherine S Virgo; Randal C Paniello; Michael H Johnson; Marc F Clemente; Frank E Johnson
Journal:  Int J Oncol       Date:  2002-11       Impact factor: 5.650

Review 6.  Psychosocial interventions for patients with head and neck cancer: past, present, and future.

Authors:  Cherith J Semple; Kate Sullivan; Lynn Dunwoody; W George Kernohan
Journal:  Cancer Nurs       Date:  2004 Nov-Dec       Impact factor: 2.592

7.  The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up.

Authors:  M van Agthoven; B M van Ineveld; M F de Boer; C R Leemans; P P Knegt; G B Snow; C A Uyl-de Groot
Journal:  Eur J Cancer       Date:  2001-11       Impact factor: 9.162

8.  Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET?

Authors:  Jolijn Brouwer; Asaf Senft; Remco de Bree; Emile F I Comans; Richard P Golding; Jonas A Castelijns; Otto S Hoekstra; C René Leemans
Journal:  Oral Oncol       Date:  2005-11-02       Impact factor: 5.337

9.  Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient?

Authors:  Jolijn Brouwer; Remco de Bree; Otto S Hoekstra; Richard P Golding; Johannes A Langendijk; Jonas A Castelijns; C René Leemans
Journal:  Laryngoscope       Date:  2005-10       Impact factor: 3.325

10.  [References for after-care of tumor patients].

Authors:  H Bier; M Schultze; U Ganzer
Journal:  HNO       Date:  1993-01       Impact factor: 1.284

View more
  2 in total

1.  Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy.

Authors:  Gregor Heiduschka; Anja Grah; Felicitas Oberndorfer; Lorenz Kadletz; Gabriela Altorjai; Gabriela Kornek; Fritz Wrba; Dietmar Thurnher; Edgar Selzer
Journal:  Strahlenther Onkol       Date:  2014-09-25       Impact factor: 3.621

Review 2.  [Pathological changes of the hypopharynx in the focus of imaging].

Authors:  S F Nemec; M Formanek; I M Noebauer-Huhmann; C R Krestan; J Frühwald; P Peloschek; A M Herneth; C Czerny
Journal:  Radiologe       Date:  2009-01       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.